Evidence Against a Role for NADPH Oxidase Modulating Hepatic Vascular Tone in Cirrhosis

Gastroenterology

Volumn 133, Issue 3, 2007, Pages 959-966

  Gracia Sancho, Jorge ^a   Laviña, Bàrbara ^a   Rodríguez Vilarrupla, Aina ^a   Brandes, Ralf P ^b   Fernández, Mercedes ^a   Bosch, Jaume ^a   García Pagán, Joan Carles ^a  

^a IMDIM   (Spain)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; APOCYNIN; CARBON TETRACHLORIDE; NITRITE REDUCTASE [NAD(P)H]; OXYGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; LIVER BLOOD FLOW; LIVER BLOOD VESSEL; LIVER CIRRHOSIS; LIVER PERFUSION; MALE; MESENTERY BLOOD FLOW; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; SPLANCHNIC BLOOD FLOW; SUPERIOR MESENTERIC ARTERY; VASCULAR RESISTANCE;

EID: 34548531554     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.06.021     Document Type: Article

References (35)

1. Bosch J., and Garcia-Pagan J.C. Complications of cirrhosis. I. Portal hypertension. J Hepatol 32 (2000) 141-156
2. Gupta T.K., Toruner M., Chung M.K., et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 28 (1998) 926-931
3. Van de C.M., Van Pelt J.F., Nevens F., et al. Low NO bioavailability in CCl4 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: A comparison of two portal hypertensive rat models with healthy controls. Comp Hepatol 2 (2003) 2
4. Graupera M., Garcia-Pagan J.C., Pares M., et al. Cyclooxyenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol 39 (2003) 515-521
5. Gracia-Sancho J., Laviña B., Rodriguez-Vilarrupla A., et al. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfussion pressure in cirrhotic rat livers. J Hepatol 47 (2007) 220-227
6. Rockey D.C., and Chung J.J. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 114 (1998) 344-351
7. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87 (2000) 840-844
8. Hink U., Li H., Mollnau H., et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88 (2001) E14-E22
9. Li J.M., and Shah A.M. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 287 (2004) R1014-R1030
10. Gracia-Sancho J., Laviña B., Rodriguez-Vilarrupla A., et al. Oxidative stress reduces nitric oxide biodisponibility and may contribute to endothelial dysfunction of cirrhotic livers. J Hepatol 44 S2 (2006) S75
11. Hernandez-Guerra M., Garcia-Pagan J.C., Turnes J., et al. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology 43 (2006) 485-491
12. Kono H., Rusyn I., Yin M., et al. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest 106 (2000) 867-872
13. Bataller R., Schwabe R.F., Choi Y.H., et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112 (2003) 1383-1394
14. Carmiel-Haggai M., Cederbaum A.I., and Nieto N. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 19 (2005) 136-138
15. Harada H., Hines I.N., Flores S., et al. Role of NADPH oxidase-derived superoxide in reduced size liver ischemia and reperfusion injury. Arch Biochem Biophys 423 (2004) 103-108
16. Graupera M., Garcia-Pagan J.C., Abraldes J.G., et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 37 (2003) 172-181
17. Cotter M.A., and Cameron N.E. Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci 73 (2003) 1813-1824
18. Beswick R.A., Dorrance A.M., Leite R., et al. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 38 (2001) 1107-1111
19. Hu L., Zhang Y., Lim P.S., et al. Apocynin but not l-arginine prevents and reverses dexamethasone-induced hypertension in the rat. Am J Hypertens 19 (2006) 413-418
20. Fernandez M., Garcia-Pagan J.C., Casadevall M., et al. Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesis. Gastroenterology 110 (1996) 1529-1535
21. Graupera M., Garcia-Pagan J.C., Titos E., et al. 5-Lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology 122 (2002) 387-393
22. Brandes R.P., Koddenberg G., Gwinner W., et al. Role of increased production of superoxide anions by NAD(P)H oxidase and xanthine oxidase in prolonged endotoxemia. Hypertension 33 (1999) 1243-1249
23. Janiszewski M., Souza H.P., Liu X., et al. Overestimation of NADH-driven vascular oxidase activity due to lucigenin artifacts. Free Radic Biol Med 32 (2002) 446-453
24. Matei V., Rodriguez-Vilarrupla A., Deulofeu R., et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology 44 (2006) 44-52
25. Shah V., Toruner M., Haddad F., et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 117 (1999) 1222-1228
26. Cave A.C., Brewer A.C., Narayanapanicker A., et al. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8 (2006) 691-728
27. Adachi T., Togashi H., Suzuki A., et al. NAD(P)H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology 41 (2005) 1272-1281
28. Gujral J.S., Hinson J.A., Farhood A., et al. NADPH oxidase-derived oxidant stress is critical for neutrophil cytotoxicity during endotoxemia. Am J Physiol Gastrointest Liver Physiol 287 (2004) G243-G252
29. Colmenero J., Bataller R., Sancho-Bru P., et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology 132 (2007) 687-697
30. Angermayr B., Fernandez M., Mejias M., et al. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats. Gut 56 (2007) 560-564
31. Vignais P.V. The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell Mol Life Sci 59 (2002) 1428-1459
32. Cai H., Griendling K.K., and Harrison D.G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 24 (2003) 471-478
33. Brandes R.P., and Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res 65 (2005) 16-27
34. Van Buul J.D., Fernandez-Borja M., Anthony E.C., et al. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid Redox Signal 7 (2005) 308-317
35. Ago T., Kitazono T., Ooboshi H., et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 109 (2004) 227-233